Company intelligence / Profile preview
Amlogenyx
Novato, California, United Statesamlogenyx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Amlogenyx is advancing a novel AAV9-based gene therapy to deliver cathepsin A (PPCA) enzyme to the brain, which has shown substantial reduction of amyloid beta (Aβ42) accumulation in preclinical murine models, exceeding results of monoclonal antibody therapies targeting the same pathology. No clinical data are yet available.[1][2][3]
- Therapeutic areas
- Neurology
- Modalities
- Gene therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
St. Jude Children's Research Hospital (scientific/technology origins)Ultragenyx (manufacturing and IP platform)
Beyond the preview
Go deeper on Amlogenyx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amlogenyx.